Alternative Tests Make the Grade
Toxicity testing is absolutely necessary for assessing the safety of substances in food, air, and water, in the workplace and at home. Although there are several tried-and-true toxicity assays, the search is always on for methods that can even better predict toxic effects. As scientific understanding of the effects of environmental toxicants grows, new tests are needed to evaluate previously unexamined end points and to take advantage of advances in biotechnology and the growing knowledge of how toxicants work at the molecular and cellular levels. Another issue is how to develop tests that can reliably and accurately assess toxicity using less time, money, and materials, and with greater regard for animal welfare. The Interagency Coordinating Committee on the Validation of Alternative Methods (ICC-VAM) was established in 1997 to address these needs through the development, validation, acceptance, and harmonization of new and revised toxicological test methods throughout the federal government.
ICCVAM is made up of representatives from the NIEHS and 13 other federal regulatory and research agencies. The National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM, pronounced "nigh SEE tum") was created in 1998 to support ICCVAM's goals. NICEATM is housed on the NIEHS campus in Research Triangle Park, North Carolina. In collaboration with ICCVAM, center staff review all nominations for assays to be evaluated and decide whether there are sufficient data for an independent public scientific peer review to proceed. NICEATM also assists in arranging the peer review sessions and organizing the expert panels and workshops. The center prepares and publishes reports and information about each validated test including a detailed description of the methods and data used to substantiate its validity. This information, along with ICCVAM's recommendations on the test's use, is sent to research and regulatory agencies, which then decide whether and how the method will fit into their program activities.
The goal of ICCVAM is to facilitate the scientific validation and regulatory acceptance of new test methods that are more predictive of human health and environmental effects than current methods, and that will reduce, refine, and replace animal use where scientifically possible. Reduction means employing methods that use fewer animals than standard historical models, or that obtain more types of information from each animal. Refinement refers to enhancing the animals' wellbeing, for instance, by using more humane end points to end studies before the onset of significant pain and distress.
Replacement can include using nonanimal systems or lower species (such as singlecelled organisms) in place of higher species.
Alternative methods also include in vitro methods, such as cell cultures, and computer technologies that allow scientists to use existing animal data to build predictive models. In reviewing each method, the peer review panel considers two overall questions in addition to a series of detailed test-specific questions. First, has the method been evaluated sufficiently and is its performance satisfactory to support its proposed use? And second, has there been adequate consideration of animal welfare in terms of reduction, refinement, and replacement? To date, ICCVAM has completed reviews on two alternative test methods-the murine local lymph node assay (LLNA) and the Corrositex assay.
LLNA. The first peer review panel evaluated the LLNA in September ove8. Already used for over a decade to gauge the potential of chemicals to cause allergic contact dermatitis in a research setting, the assay was recommended for fullfledged endorsement as a viable stand-alone test method.
Traditionally, guinea pig assays are used to determine the potential of a chemical or product to cause an allergic contact dermatitis response. Such assays involve the repeated application of a test substance to the guinea pigs' skin and examination of the site over 4 weeks to see whether an allergic response has occurred or whether a delayed-sensitivity response can be induced with additional applications of the substance. While considered fairly reliable, these assays may produce false positive and false negative results. In addition, the results are somewhat subjective and require considerable experience and expertise to be accurately interpreted.
While the traditional assays measure the allergic reaction itself, the LLNA measures the lymphocyte proliferation response, a necessary and inevitable biological precursor to sensitization. In the LLNA, the test substance is applied to the ears of 4-5 young adult mice for 3 consecutive days. The animals are rested for 2 days and then euthanized, and their lymph nodes are removed and examined. If the test substance spurs an immune response, there will be a rapid proliferation of lymph cells after the exposure. This measurable increase in lymph cells can be used to characterize the sensitization potential of the test substance.
The peer review panel evaluated data on 209 chemicals. Of these, both LLNA and guinea pig data were available for 126 chemicals, and both LLNA and human data were available for 74 chemicals. From the data submitted, the panel concluded that the accuracy (the proportion of correct outcomes) of the LLNA was about 86% when compared to data from all guinea pig tests and about 72% when compared to human data (guinea pig tests have an accuracy of about 73% compared to human data). In terms of accuracy, sensitivity (the proportion of all test substances that are correctly classified as positive), specificity (the proportion of all test substances that are correctly classified as negative), positive and negative predictivity (the proportion of positive and negative test substances that are correctly identified by the assay as such), and comparability to human data, the LLNA performs at least as well as traditional guinea pig assays and in some cases was a better predictor of a human allergic response. The LLNA was therefore determined to be a viable alternative to traditional guinea pig assays for identifying strong to moderate chemical sensitizing agents and predicting the risk of human allergic contact dermatitis.
The LLNA offers many advantages over traditional guinea pig assays. It allows scientists to measure changes in allergic response over several concentrations. Because the method evaluates the induction phase rather than the elicitation phase of the response, the mice used in the LLNA don't suffer the methods to use these guidelines during the planning stages. This will increase the likelihood that data needed to characterize the usefulness and limitations of the test method will be generated. It will also increase the likelihood that there will be adequate information for agencies to make decisions on the acceptability of the method." The new guidance was opened for public comment with a 2 December 1999 Federal Register notice. Depending on the comments received, the guidance may be revised further and reissued later this year. -Susan M. Booker Environmental Health Perspectives * Volume 108, Number 3, March 2000
